Cargando…

Heart Failure Treatments Such As Angiotensin Receptor/Neprilysin Inhibitor Improve Heart Failure Status and Glucose Metabolism

A recent study suggested that angiotensin receptor/neprilysin inhibitor (ARNI; sacubitril/valsartan) can improve functional capacity and cardiac reverse remodeling in patients with heart failure with reduced ejection fraction (HFrEF). Another study suggested that ARNI reduced glycated hemoglobin (Hb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kashiwagi, Yusuke, Nagoshi, Tomohisa, Ogawa, Kazuo, Kawai, Makoto, Yoshimura, Michihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Cardiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971101/ https://www.ncbi.nlm.nih.gov/pubmed/35371876 http://dx.doi.org/10.7759/cureus.22762

Ejemplares similares

Effects of angiotensin receptor‐neprilysin inhibitor on insulin resistance in patients with heart failure
por: Kashiwagi, Yusuke, et al.
Publicado: (2023)

Efficacy of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors in the Treatment of Chronic Heart Failure: A Review of Landmark Trials
por: Bratsos, Sosipatros
Publicado: (2019)

Relationship between haemodynamic indicators and haemogram in patients with heart failure
por: Oh, Takuya, et al.
Publicado: (2022)

Comparison of Efficacy and Safety of Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis
por: Haseeb, Muhammad Talha, et al.
Publicado: (2023)

Effects of Angiotensin Receptor-Neprilysin Inhibitors Versus Enalapril or Valsartan on Patients With Heart Failure: A Systematic Review and Meta-Analysis
por: Jain, Arpit, et al.
Publicado: (2023)

Association between plasma B-type natriuretic peptide and anaemia in heart failure with or without ischaemic heart disease: a retrospective study
por: Tominaga, Mitsutoshi, et al.
Publicado: (2019)

Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond
por: Singh, Jagdeep SS, et al.
Publicado: (2015)

Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure
por: Greenberg, Barry
Publicado: (2020)

Comparing angiotensin receptor–neprilysin inhibitors with sodium–glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus
por: Tsai, Ming-Lung, et al.
Publicado: (2023)

Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease
por: Cho, In-Jeong, et al.
Publicado: (2021)

The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure
por: Fadiran, Olusayo, et al.
Publicado: (2021)

Low triiodothyronine levels correlate with high B-type natriuretic peptide levels in patients with heart failure
por: Takahashi, Hirotake, et al.
Publicado: (2021)

Is there a place for angiotensin receptor-neprilysin inhibitors in the treatment of heart failure patients after heart transplantation?
por: Gulin, Dario, et al.
Publicado: (2019)

Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence
por: Choi, Hong-Mi, et al.
Publicado: (2020)

Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure
por: Sun, Yuxi, et al.
Publicado: (2021)

Optimization of Cardiac Metabolism in Heart Failure
por: Nagoshi, Tomohisa, et al.
Publicado: (2011)

Getting the “Right” Perspective on Angiotensin Receptor–Neprilysin Inhibition in Heart Failure
por: Verbrugge, Frederik H., et al.
Publicado: (2020)

Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure
por: Dizaye, Kawa, et al.
Publicado: (2019)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Heart Failure: An Umbrella Review
por: Roy, Raj, et al.
Publicado: (2023)

LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure and hypertension
por: Lefkowitz, Martin P
Publicado: (2011)

Angiotensin receptor neprilysin inhibitor in inotrope dependent heart failure patients: A case series
por: Taghavi, Sepideh, et al.
Publicado: (2020)

Relevance of Neutrophil Neprilysin in Heart Failure
por: Prausmüller, Suriya, et al.
Publicado: (2021)

Outcome of angiotensin receptor-neprilysin inhibitor on anxiety and depression in heart failure with reduced ejection fraction vs. heart failure with preserved ejection fraction
por: Malik, Jahanzeb, et al.
Publicado: (2021)

Sodium-Glucose Co-transporter 2 Inhibitors/Gliflozins: A New Miracle Therapy for Heart Failure Patients Irrespective of Diabetes Status?
por: Ehsan, Paghunda, et al.
Publicado: (2022)

Sodium-glucose cotransporter 2 inhibitors in obese patients with heart failure
por: Kato, Shingo, et al.
Publicado: (2023)

LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure
por: Lefkowitz, Martin P
Publicado: (2015)

Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure
por: Pfau, Daniel, et al.
Publicado: (2019)

Transient Receptor Potential Channels, Natriuretic Peptides, and Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure
por: Ding, Kun, et al.
Publicado: (2022)

Association Between Copayment Amount and Filling of Medications for Angiotensin Receptor Neprilysin Inhibitors in Patients With Heart Failure
por: Mukhopadhyay, Amrita, et al.
Publicado: (2022)

Clinical efficacy of angiotensin receptor-neprilysin inhibitor in de novo heart failure with reduced ejection fraction
por: Park, Su Yeong, et al.
Publicado: (2023)

Effects of Sodium-Glucose Cotransporter Inhibitor Use in Type 2 Diabetes Mellitus Patients With Heart Failure
por: Choday, Silpa, et al.
Publicado: (2023)

Potential Benefits of Sodium-Glucose Transporter-2 Inhibitors in the Symptomatic and Functional Status of Patients With Heart Failure: A Systematic Review and Meta-Analysis
por: Bhalla, Sushen, et al.
Publicado: (2022)

The Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Improving Morbidity and Mortality of Heart Failure: A Systematic Review
por: Thiagaraj, Suvedha, et al.
Publicado: (2023)

Impact of Mineralocorticoid Receptor Antagonists in the Treatment of Heart Failure: Targeting the Heart Failure Cascade
por: Jadhav, Uday, et al.
Publicado: (2023)

Combined Angiotensin Receptor–Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure
por: Trivedi, Rishi K., et al.
Publicado: (2018)

Cost-Effectiveness of Earlier Transition to Angiotensin Receptor Neprilysin Inhibitor in Patients With Heart Failure and Reduced Ejection Fraction
por: Grant, Andrew D.M., et al.
Publicado: (2020)

Increased concentrations of bioactive adrenomedullin subsequently to angiotensin‐receptor/neprilysin‐inhibitor treatment in chronic systolic heart failure
por: Arfsten, Henrike, et al.
Publicado: (2020)

The Impact of Angiotensin Receptor–Neprilysin Inhibitors on Arrhythmias in Patients with Heart Failure: A Systematic Review and Meta-analysis
por: Mujadzic, Hata, et al.
Publicado: (2022)

The angiotensin receptor and neprilysin inhibitor, LCZ696, in heart failure: A meta-analysis of randomized controlled trials
por: Chen, Yan, et al.
Publicado: (2022)

Real-world Practical Experience of Angiotensin Receptor-neprilysin Inhibitor in Older Japanese Patients with Chronic Heart Failure
por: Komatsu, Toshinori, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lgvkhjlokqvoe1744k7k7cgsm8